Tubulis and Glycotope announced that they have signed a research and feasibility agreement, providing Glycotope access to Tubulis’ proprietary antibody drug conjugate (ADC) technologies.
Glycotope will have non-exclusive access to Tubulis’ Tub-tag® technology for one of its ADC candidates. Tub-tag® allows for site-specific and stable ADC conjugation by implementing biology-inspired aspects for enhanced ADC stability.
“We are pleased to enter this collaboration and working closely with Tubulis on identifying novel ADC candidates,” said Sven Bahrke, Senior Director at Glycotope. “We believe that Tubulis’ ADC discovery and development technologies add unique and innovative aspects to the field of ADC conjugation.”
In addition, Glycotope receives the option to evaluate the potential of Tubulis’ ADC screening platform P5.
“This agreement with Glycotope, an experienced antibody developer in the oncology area, will enable us to further validate our advanced ADC technologies. We look forward to collaborate with the Glycotope team to create novel, uniquely stable therapeutic candidates,” said Dominik Schumacher, CEO of Tubulis.
Financial terms of the collaboration were not disclosed.